392 related articles for article (PubMed ID: 29307892)
21. [Glucose renal excretion as diabetes treatment: From an old diagnostic method to a new way of treatment].
Dalama B; Biagetti B; Mesa J
Med Clin (Barc); 2016 May; 146(10):460-4. PubMed ID: 26823105
[No Abstract] [Full Text] [Related]
22. Sodium-glucose cotransporter 2 inhibitors and diabetic ketoacidosis.
Bloomgarden ZT
J Diabetes; 2016 Mar; 8(2):175-6. PubMed ID: 26611882
[No Abstract] [Full Text] [Related]
23. [Empagliflozin in the elderly].
Berrut G; Boureau AS; Trochu JN; Genet B; de Decker L; Hanon O
Geriatr Psychol Neuropsychiatr Vieil; 2021 Jun; 19(2):137-147. PubMed ID: 34165436
[TBL] [Abstract][Full Text] [Related]
24. Research digest: SGLT2 inhibition in kidney and liver disease.
Preiss D; Sattar N
Lancet Diabetes Endocrinol; 2019 Jun; 7(6):427. PubMed ID: 31103176
[No Abstract] [Full Text] [Related]
25. The impact of sodium glucose co-transporter 2 inhibitors on non-alcoholic fatty liver disease.
Chrysavgis L; Papatheodoridi AM; Chatzigeorgiou A; Cholongitas E
J Gastroenterol Hepatol; 2021 Apr; 36(4):893-909. PubMed ID: 33439540
[TBL] [Abstract][Full Text] [Related]
26. Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials.
Kamstra R; Durkin M; Cai J; Bookhart B; Lafeuille MH; Pilon D; Tiggelaar S; Manceur AM; Lefebvre P
J Med Econ; 2019 Mar; 22(3):280-287. PubMed ID: 30575426
[TBL] [Abstract][Full Text] [Related]
27. Diabetes and kidney disease: the role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes.
Mende CW
Curr Med Res Opin; 2017 Mar; 33(3):541-551. PubMed ID: 27977314
[TBL] [Abstract][Full Text] [Related]
28. Slowing Progression in CKD: DAPA CKD and Beyond.
Larmour K; Levin A
Clin J Am Soc Nephrol; 2021 Jul; 16(7):1117-1119. PubMed ID: 33692116
[No Abstract] [Full Text] [Related]
29. Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough?
Raschi E; Poluzzi E; Fadini GP; Marchesini G; De Ponti F
Diabetes Obes Metab; 2018 Dec; 20(12):2711-2723. PubMed ID: 30003655
[TBL] [Abstract][Full Text] [Related]
30. What is the place of new SGLT-2 inhibitors in therapy and on the formulary?
Mehr SR; Zimmerman MP
Am J Manag Care; 2014 Mar; 20(4 Spec No.):E1. PubMed ID: 25618509
[No Abstract] [Full Text] [Related]
31. Bolstering your armamentarium with SGLT2 inhibitors.
Novak LM; Kruger DF
Nurse Pract; 2017 Oct; 42(10):28-34. PubMed ID: 28926495
[TBL] [Abstract][Full Text] [Related]
32. SGLT2 Inhibitors and the Diabetic Kidney.
Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
[TBL] [Abstract][Full Text] [Related]
33. Considerations for SGLT2 inhibitor use in post-transplantation diabetes.
Hecking M; Jenssen T
Nat Rev Nephrol; 2019 Sep; 15(9):525-526. PubMed ID: 31235880
[No Abstract] [Full Text] [Related]
34. Usefulness of Empagliflozin Versus Liraglutide for Prevention of Cardiovascular Mortality.
Arbel R; Hammerman A; Azuri J
Am J Cardiol; 2018 Sep; 122(6):981-984. PubMed ID: 30075890
[TBL] [Abstract][Full Text] [Related]
35. Hot Topics in Primary Care: Role of the Kidney and SGLT-2 Inhibition in Type 2 Diabetes Mellitus.
Miller K; Miller EM
J Fam Pract; 2015 Dec; 64(12 Suppl):S54-8. PubMed ID: 26845015
[TBL] [Abstract][Full Text] [Related]
36. EMPA-REG OUTCOME: The Nephrologist's Point of View.
Wanner C
Am J Cardiol; 2017 Jul; 120(1S):S59-S67. PubMed ID: 28606346
[TBL] [Abstract][Full Text] [Related]
37. Dapagliflozin-Associated Diabetic Ketoacidosis.
Chakinala RC; Chang AP; Solanki S; Haq KF; Cho R
Am J Ther; 2018; 25(6):e765-e766. PubMed ID: 29672334
[No Abstract] [Full Text] [Related]
38. [Introduction].
García SD
Med Clin (Barc); 2013 Sep; 141 Suppl 2():1-2. PubMed ID: 24444516
[No Abstract] [Full Text] [Related]
39. SGLT2-inhibitors in type-2 diabetes: The remaining questions!
Rajput R; Ved J
Diabetes Metab Syndr; 2017 Nov; 11 Suppl 1():S433-S438. PubMed ID: 28395977
[TBL] [Abstract][Full Text] [Related]
40. [SGLT-2 inhibition with canagliflozin: a new option for the treatment of type 2 diabetes].
Seufert J
Dtsch Med Wochenschr; 2014 Feb; 139 Suppl 2():S52-8. PubMed ID: 24481633
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
